Search | IOVS | ARVO Journals

View

Showing 1 – 11 of 11

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Predictability of the 12-week dosing status at Week 48 for patients receiving brolucizumab in HAWK and HARRIER

Pravin U Dugel; Gabriele Elisabeth Lang; Sam Razavi; Andreas Weichselberger; Yuichiro Ogura; David M Brown

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1455. doi:

ARVO Annual Meeting Abstract July 2018

Comparative assessment of anatomical outcomes for nAMD patients treated with brolucizumab and aflibercept: 16-week data from the HAWK and HARRIER studies

Rishi P Singh; Andreas Weichselberger; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1464. doi:

ARVO Annual Meeting Abstract July 2018

Topical VEGF receptor inhibitor, LHA510, did not demonstrate efficacy in a Proof-of-Concept study in patients with neovascular age-related macular degeneration (nv AMD)

Stephen H Poor; Christopher M Adams; Michael Ferriere; Andreas Weichselberger; Cynthia L Grosskreutz; Georges Weissgerber

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2394. doi:

ARVO Annual Meeting Abstract July 2018

Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER

Glenn J Jaffe; Adrian H C Koh; Yuichiro Ogura; Andreas Weichselberger; Frank G. Holz; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1624. doi:

ARVO Annual Meeting Abstract September 2016

The effect of brolucizumab applied by microvolume injection or infusion in patients with neovascular age-related macular degeneration

Chirag Jhaveri; Andreas Wenzel; Andreas Weichselberger

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5061. doi:

ARVO Annual Meeting Abstract September 2016

Association of fluid recurrence with visual maintenance following the loading phase in anti-VEGF therapy for neovascular AMD

Sebastian M Waldstein; Victor Chong; Michael Larsen; James Warburton; Andreas Weichselberger; Jonathan Wright; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):533. doi:

ARVO Annual Meeting Abstract September 2016

A 2-year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age-related macular degeneration: testing an alternative treatment regimen

Pravin U Dugel; James Warburton; Andreas Weichselberger; Peter Sallstig

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5018. doi:

ARVO Annual Meeting Abstract June 2015

Efficacy of RTH258 (ESBA1008), an Anti-VEGF Agent, Applied by Microvolume Injection or Infusion in Subjects with Neovascular AMD

Brian B Berger; Susan E Yanni; Andreas Wenzel; Andreas Weichselberger; Jean Pierre Hubschman

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):821. doi:

ARVO Annual Meeting Abstract June 2015

OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD

Lawrence J Singerman; Andreas Weichselberger; Peter Sallstig

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4801. doi:

ARVO Annual Meeting Abstract March 2012

A Pilot Multicenter Clinical Study to Evaluate a Mobile Computing System for Remote Monitoring of Retinal Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration (AMD)

Peter K. Kaiser; Andrew N. Antoszyk; Alexander M. Eaton; Yi-Zhong Wang; Dirk Sauer; Annemarie Weisberger; Andreas Weichselberger; Craig H. Smith; 2407 Study Group

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4403. doi:

Physiology and Pharmacology January 2010

The Effects of a Flexible Visual Acuity–Driven Ranibizumab Treatment Regimen in Age-Related Macular Degeneration: Outcomes of a Drug and Disease Model

PDF

Frank G. Holz; Jean-François Korobelnik; Paolo Lanzetta; Paul Mitchell; Ursula Schmidt-Erfurth; Sebastian Wolf; Sabri Markabi; Heinz Schmidli; Andreas Weichselberger
TAGS: disease models, ranibizumab, treatment protocols, visual acuity, age-related macular degeneration, injections
Invest. Ophthalmol. Vis. Sci.. 2010; 51(1):405-412. doi: https://doi.org/10.1167/iovs.09-3813

Advertisement